Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: TrialsWest
Location: 6 Barrington Street, Spearwood, WA, 6163
Research Centre: Respiratory Clinical Trials
Location: 83 Fullarton Rd, Kent Town SA, Australia
Lead Doctors: Professor Peter Bremner; Dr. Michael Chia
Ethics Committee: This study has been reviewed and approved by Bellberry HREC Human Research Ethics Committee

Background

Asthma is a condition that makes breathing difficult due to airways narrowing due to inflammation and swelling. For most asthma patients, their treatment is successful and can provide long-term control. However, 10- 15% of asthmatics still show symptoms despite using maximum recommended treatments. 

This study seeks to investigate the potential benefits of a potential new treatment (Itolizumab) to help manage uncontrolled moderate-to-severe asthma.

The study seeks adults aged 18 to 75 years old who are diagnosed with moderate-to-severe asthma and are currently using asthma medication. Participants must attend a minimum of 9 study site visits at the research site over approximately 12 weeks.

Why Participate? 

• You will be seen by a specialist to help with your asthma condition.
• You will receive an optimal treatment plan to help manage your asthma after your participation in the study is completed.
• You may prevent further asthma complications.
• You will receive a payment of $150 to cover travel, parking, meals and other expenses whilst participating in this study.
• You will be helping to advance medical research.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Adults aged 18-75 years old diagnosed with uncontrolled moderate-to-severe asthma.
• Must have been taking medication for their asthma for at least 3 months.
• Must have experienced a significant asthma exacerbation within the past 12 months.
• Able to attend a minimum of 9 study visits at the research site over approximately 12 weeks.